Verve Therapeutics(VERV) - 2023 Q4 - Annual Results

Exhibit 99.1 Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results Three Clinical Stage Programs Targeting PCSK9 and ANGPTL3 Expected in 2024 Announced First Human Proof-of-Concept Data for In Vivo Base Editing from Ongoing Heart-1 Phase 1b Clinical Trial of VERVE-101 in November 2023 Cash, Cash Equivalents and Marketable Securities of $624 Million with Cash Runway into Late 2026 BOSTON — Feb. 27, 2024 — Verve Therapeutics, a clinical-stage biotechnolo ...